Table 7 Risk of fracture associated with the use of bisphosphonates
Adjusted OR (95 % CI) any fracture | Adjusted OR (95 % CI) accidental fracture | Adjusted OR (95 % CI) hip fracture | |
|---|---|---|---|
Use of bisphosphonate a | |||
No | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
Yes | 4.12 (3.56–4.77) | 4.21 (3.55–5.0) | 5.20 (4.06–6.67) |
Extent of disease a | |||
Localised | |||
No bisphosphonate | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
Bisphosphonate | 5.89 (2.81–12.38) | 5.46 (2.38–12.50) | 5.16 (0.61–43.55) |
Locally advanced or Metastatic | |||
No bisphosphonate | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
Bisphosphonate | 2.03 (1.42–2.90) | 1.97 (1.17–3.33) | 1.76 (0.79–3.91) |
Unknown | |||
No bisphosphonate | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
Bisphosphonate | 4.85 (4.11–5.73) | 4.62 (3.83–5.56) | 6.01 (4.61–7.83) |